Pharma Journalist -

Ligand Pharmaceuticals Incorporated announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program was…
Read More...

Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, announced a collaboration with…
Read More...

MacroGenics, Inc. and I-Mab Biopharma (I-Mab) announced that the companies have entered into an exclusive collaboration and license agreement to develop and commercialize enoblituzumab.…
Read More...

Catalent, Inc. announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an…
Read More...

ReachBio Research Labs (trade name under ReachBio LLC), a CRO specializing in primary cell assay services and products, is now offering off-target toxicity and linker stability assay…
Read More...

CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic…
Read More...

Lonza announced the completion of a $15M multi-phase expansion of its solid oral dose development and manufacturing capabilities and capacity at its Tampa, FL (USA) site. The expansion…
Read More...

NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced that it has initiated a pivotal Phase 2b/3 study for…
Read More...

Altimmune, Inc. announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent…
Read More...

ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced that it has entered into a non-exclusive license and collaboration agreement with Roche. Under the terms of…
Read More...